Report : Asia Pacific Acne Medication Market Forecast to 2030 - Regional Analysis - by Therapeutic Class (Retinoids, Benzoyl Peroxide, Antibiotics, Salicylic Acid, and Others), Formulation (Topical Medication and Oral Medication), Type (Prescription Medicine and Over-the-Counter Medicine), Acne Type (Non-Inflammatory Acne and Inflammatory Acne), and Distribution Channel (Pharmacies and Drug Stores, Retail Stores, and E-Commerce)
At 7.4% CAGR, Asia Pacific Acne Medication Market is Speculated to be Worth US$ 2,672.90 Million by 2030, says Business Market Insights
According to Business Market Insights' research, the Asia Pacific acne medication market was valued at US$ 1,508.26 million in 2022 and is expected to reach US$ 2,672.90 million by 2030, registering a CAGR of 7.4% from 2023 to 2030. Individualized treatment programs based on cutting-edge technologies and data-driven strategies and upsurge in need for organic and natural treatments are among the critical factors attributed to the Asia Pacific acne medication market expansion.
Adopting advanced technologies and data-driven approaches in the Asia Pacific acne medication market opens up new avenues for research and development. By collecting and analyzing patient data, researchers can gain valuable insights into the underlying causes of acne, identify patterns and trends in treatment responses, and discover new potential targets for therapeutic interventions. This can drive the development of novel medications, innovative treatment strategies, and more personalized skincare products tailored to the diverse needs of acne patients. By leveraging artificial intelligence (AI), machine learning algorithms, genetic testing, and other cutting-edge tools, healthcare providers can now analyze vast data to gain a better understanding of patient's unique skin conditions, genetic predispositions, lifestyle factors, and treatment responses. This personalized approach allows for the development of tailored treatment plans specifically designed to address each patient's individual needs.
In March 2021, Onegevity, a health intelligence firm and a subsidiary of Thorne HealthTech, teamed up with Unilever, one of the top manufacturers of beauty and personal care products worldwide, to enable a more personalized approach to acne intervention and treatment. The scientific collaboration is meant to investigate the potential of multi-omics, or the integration of different biological disciplines, to enable more individualized approaches to treating acne. The collaboration aims to create new diagnostic models that can unlock customized acne treatment plans by utilizing Onegevity's AI and machine learning capabilities that allow the evaluation of billions of biological characteristics affecting a person's health. Personalized treatment plans help to optimize treatment efficacy by taking into account patients' specific characteristics and factors that may influence their response to acne medication. Based on such patient-specific data, healthcare providers can prescribe treatments that are more likely to be effective for that particular individual. This improves the chances of successfully treating acne and reduces the likelihood of side effects and adverse reactions, leading to better patient outcomes and increased satisfaction. Thus, integrating advanced technologies and data-driven approaches for designing personalized treatment plans creates significant opportunities for innovation, growth, and improved patient outcomes in the Asia Pacific acne medication market.
On the contrary, side effects associated with acne medication hampers the growth of Asia Pacific acne medication market.
Based on therapeutic class, the Asia Pacific acne medication market is segmented into retinoids, benzoyl peroxide, antibiotics, salicylic acid, and others. The retinoids segment held 33.6% share of the Asia Pacific acne medication market in 2022, amassing US$ 506.99 million. It is projected to garner US$ 984.12 million by 2030 to expand at 8.7% CAGR during 2023-2030.
In terms of formulation, the Asia Pacific acne medication market is bifurcated into topical medication and oral medication. The topical medication segment held 68.6% share of the Asia Pacific acne medication market in 2022, amassing US$ 1,034.84 million. It is estimated to garner US$ 1,907.14 million by 2030 to expand at 8.0% CAGR during 2023-2030.
By type, the Asia Pacific acne medication market is bifurcated into prescription medicine and over-the-counter medicine. The prescription medicine segment held 65.3% share of Asia Pacific acne medication market in 2022, amassing US$ 984.72 million. It is predicted to garner US$ 1,802.41 million by 2030 to expand at 7.9% CAGR during 2023-2030.
Based on acne type, the Asia Pacific acne medication market is bifurcated into non-inflammatory acne and inflammatory acne. The inflammatory acne segment held 54.6% share of the Asia Pacific acne medication market in 2022, amassing US$ 823.08 million. It is projected to garner US$ 1,490.99 million by 2030 to expand at 7.7% CAGR during 2023-2030.
In terms of distribution channel, the Asia Pacific acne medication market is segmented into pharmacies and drug stores, retail stores, and e-commerce. The pharmacies and drug stores segment held 49.6% share of the Asia Pacific acne medication market in 2022, amassing US$ 748.80 million. It is estimated to garner US$ 1,404.27 million by 2030 to expand at 8.2% CAGR during 2023-2030.
Based on country, the Asia Pacific acne medication market is categorized into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China held 29.5% share of Asia Pacific acne medication market in 2022, amassing US$ 445.39 million. It is projected to garner US$ 943.00 million by 2030 to expand at 9.9% CAGR during 2023-2030.
Key players operating in the Asia Pacific acne medication market are Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Mayne Pharma Group Ltd, Almirall SA, Johnson & Johnson, Bausch Health Companies Inc, Galderma SA, Pfizer Inc, GSK Plc, and Viatris Inc, among others.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com